Drug Profile
Camsirubicin - Monopar Therapeutics
Alternative Names: 5-imino-13-deoxy-doxorubicin HCl; CNDO-101; GPX-150; MNPR-201Latest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator Gem Pharmaceuticals
- Developer Monopar Therapeutics
- Class Antineoplastics; Antipsoriatics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Soft tissue sarcoma
- Discontinued Psoriasis; Solid tumours
Most Recent Events
- 08 Aug 2023 Efficacy and adverse events data from phase-Ib trial in Soft tissue sarcoma released by Monopar Therapeutics
- 01 Jun 2023 Updated efficacy data from a phase I trial in Soft tissue sarcoma released by Monopar Therapeutics
- 14 Feb 2023 Adverse events data from a phase I trial in Soft tissue sarcoma released by Monopar Therapeutics